| Document Date: 2014-06-17 10:17:12
Open Document File Size: 82,51 KBShare Result on Facebook
City Oxford / Newcastle / / Company e-Therapeutics plc / CommStrat Group / / Country United States / United Kingdom / / / Event Company Listing Change / FDA Phase / / Facility University of California San Diego Moores Cancer Centre / / IndustryTerm chemical biology / trial protocols / biotechnology / cancer treatment / / MedicalCondition cancer / secondary brain cancers / dose-limiting fatigue / progressive disease / tumour / I ETS2101 brain cancer / advanced solid tumours / brain cancer / disorders / / Organization US Food and Drug Administration / University of California San Diego Moores Cancer Centre / / Person Ted Agne / Steve Medlicott / Malcolm Young / Duncan Monteith / Melanie Toyne Sewell / Fred Walsh / Stefanie Bacher / / / Product ETS2101 / / Technology drug discovery / biotechnology / trial protocols / / URL www.panmure.com / www.etherapeutics.co.uk / /
SocialTag |
e-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial Oxford and Newcastle, UK, 8 May[removed]e-Therapeutics plc (AIM:ETX) announces today that the US Food and Drug Administration (FDA) h